C90.3
Solitary plasmacytoma
Clinical Classification Guidelines
Inclusion Terms
- Localized malignant plasma cell tumor NOS
- Plasmacytoma NOS
- Solitary myeloma
Medical Intelligence & Overview
Solitary plasmacytoma is a type of cancer characterized by a single abnormal growth of plasma cells, which are a component of the immune system responsible for producing antibodies. Unlike multiple myeloma, which involves multiple areas of abnormal plasma cell growth throughout the bones or bone marrow, a solitary plasmacytoma typically occurs as a single tumor. This condition can develop in bones or soft tissues and is classified as a localized malignant plasma cell tumor, often referred to as plasmacytoma NOS (not otherwise specified). Early detection and appropriate management are critical for better outcomes.
Causes & Symptoms
Clinical Causes: Although the exact cause of solitary plasmacytoma remains unknown, research indicates that genetic mutations and environmental factors may contribute. Previous radiation exposure or certain medications may also play a role, but these links are not definitively established. There are no clear hereditary patterns associated with this disease.
Key Symptoms: Localized pain or swelling at the tumor site, often in bones such as the spine, skull, ribs, or long bones Tenderness or discomfort in the affected area In some cases, neurological symptoms if the tumor compresses nearby nerves, such as tingling or weakness A noticeable lump or mass in the region where the tumor develops Less commonly, symptoms like fatigue, fever, or unintentional weight loss may occur if the disease progresses
Diagnostic & Treatment
Diagnosis Path: Diagnosing solitary plasmacytoma involves a combination of imaging studies and tissue analysis, including: - **Imaging Tests:** X-rays, MRI, or CT scans to locate the tumor and determine if it has spread beyond the initial site. - **Biopsy:** A tissue sample from the tumor is examined microscopically to confirm the presence of abnormal plasma cells. - **Blood Tests:** To assess for signs of plasma cell disorder, such as abnormal antibodies or calcium levels. - **Bone Marrow Examination:** To rule out multiple myeloma, as solitary plasmacytoma typically does not involve widespread marrow infiltration. It is essential to distinguish solitary plasmacytoma from other plasma cell disorders to determine the appropriate treatment.
Treatment Protocols: Management of solitary plasmacytoma generally involves local therapy aimed at eradicating the tumor: - **Radiation Therapy:** The primary treatment modality, delivering targeted radiation to destroy cancerous plasma cells. - **Surgical Removal:** Performed in certain cases, especially if the tumor is accessible and causes symptoms or structural issues. - **Follow-up Monitoring:** Regular imaging and blood tests are essential for detecting any signs of disease progression or recurrence. In some instances, additional treatments such as chemotherapy may be considered if there is evidence of progression toward multiple myeloma, although this is less common for solitary tumors. Prognosis depends on factors such as tumor size, location, response to initial therapy, and the potential development of multiple myeloma over time.
Clinical Advice & FAQs
Billing Guidance
Is C90.3 a billable ICD-10 code?
Yes, C90.3 is a specific, billable code that can be used to indicate a diagnosis for reimbursement purposes.
Documentation
How do I report C90.3?
Clinical documentation must specify the nature of Solitary plasmacytoma and any associated comorbidities for accurate reporting.
Cite this Clinical Reference